Cargando…

Newly developed controlled release subcutaneous formulation for tramadol hydrochloride

This study presents a drug delivery system of poly (Ɛ-caprolactone) (PCL) ribbons to optimize the pharmaceutical action of tramadol for the first time according to our knowledge. PCL ribbons were fabricated and loaded with tramadol HCl. Ribbons were prepared by slip casting technique and coated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mabrouk, Mostafa, Beherei, Hanan H., ElShebiney, Shaimaa, Tanaka, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961623/
https://www.ncbi.nlm.nih.gov/pubmed/29844731
http://dx.doi.org/10.1016/j.jsps.2018.01.014
_version_ 1783324750365327360
author Mabrouk, Mostafa
Beherei, Hanan H.
ElShebiney, Shaimaa
Tanaka, Masaru
author_facet Mabrouk, Mostafa
Beherei, Hanan H.
ElShebiney, Shaimaa
Tanaka, Masaru
author_sort Mabrouk, Mostafa
collection PubMed
description This study presents a drug delivery system of poly (Ɛ-caprolactone) (PCL) ribbons to optimize the pharmaceutical action of tramadol for the first time according to our knowledge. PCL ribbons were fabricated and loaded with tramadol HCl. Ribbons were prepared by slip casting technique and coated with dipping technique with β-cyclodextrin. The chemical integrity and surface morphology of the ribbons were confirmed using FTIR and SEM coupled with EDX. In addition, thermodynamic behavior of the fabricated ribbons was investigated using DSC/TGA. Tramadol loading into PCL ribbons, biodegradation of ribbons and tramadol release kinetics were studied in PBS.The results revealed that the formulated composition did not affect the chemical integrity of the drug. Furthermore, SEM/EDX confirmed the inclusion of tramadol into the PCL matrix in homogenous distribution pattern without any observation of porous structure. The particle size of loaded tramadol was found to be in the range of (2–4 nm). The formulated composition did not affect the chemical integrity of the drug and should be further investigated for bioavailability. Tramadol exhibited controlled release behavior from PCL ribbons up to 45 days governed mainly by diffusion mechanism. The fabricated ribbons have a great potentiality to be implemented in the long term subcutaneous delivery of tramadol.
format Online
Article
Text
id pubmed-5961623
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-59616232018-05-29 Newly developed controlled release subcutaneous formulation for tramadol hydrochloride Mabrouk, Mostafa Beherei, Hanan H. ElShebiney, Shaimaa Tanaka, Masaru Saudi Pharm J Original Article This study presents a drug delivery system of poly (Ɛ-caprolactone) (PCL) ribbons to optimize the pharmaceutical action of tramadol for the first time according to our knowledge. PCL ribbons were fabricated and loaded with tramadol HCl. Ribbons were prepared by slip casting technique and coated with dipping technique with β-cyclodextrin. The chemical integrity and surface morphology of the ribbons were confirmed using FTIR and SEM coupled with EDX. In addition, thermodynamic behavior of the fabricated ribbons was investigated using DSC/TGA. Tramadol loading into PCL ribbons, biodegradation of ribbons and tramadol release kinetics were studied in PBS.The results revealed that the formulated composition did not affect the chemical integrity of the drug. Furthermore, SEM/EDX confirmed the inclusion of tramadol into the PCL matrix in homogenous distribution pattern without any observation of porous structure. The particle size of loaded tramadol was found to be in the range of (2–4 nm). The formulated composition did not affect the chemical integrity of the drug and should be further investigated for bioavailability. Tramadol exhibited controlled release behavior from PCL ribbons up to 45 days governed mainly by diffusion mechanism. The fabricated ribbons have a great potentiality to be implemented in the long term subcutaneous delivery of tramadol. Elsevier 2018-05 2018-01-31 /pmc/articles/PMC5961623/ /pubmed/29844731 http://dx.doi.org/10.1016/j.jsps.2018.01.014 Text en © 2018 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Mabrouk, Mostafa
Beherei, Hanan H.
ElShebiney, Shaimaa
Tanaka, Masaru
Newly developed controlled release subcutaneous formulation for tramadol hydrochloride
title Newly developed controlled release subcutaneous formulation for tramadol hydrochloride
title_full Newly developed controlled release subcutaneous formulation for tramadol hydrochloride
title_fullStr Newly developed controlled release subcutaneous formulation for tramadol hydrochloride
title_full_unstemmed Newly developed controlled release subcutaneous formulation for tramadol hydrochloride
title_short Newly developed controlled release subcutaneous formulation for tramadol hydrochloride
title_sort newly developed controlled release subcutaneous formulation for tramadol hydrochloride
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5961623/
https://www.ncbi.nlm.nih.gov/pubmed/29844731
http://dx.doi.org/10.1016/j.jsps.2018.01.014
work_keys_str_mv AT mabroukmostafa newlydevelopedcontrolledreleasesubcutaneousformulationfortramadolhydrochloride
AT behereihananh newlydevelopedcontrolledreleasesubcutaneousformulationfortramadolhydrochloride
AT elshebineyshaimaa newlydevelopedcontrolledreleasesubcutaneousformulationfortramadolhydrochloride
AT tanakamasaru newlydevelopedcontrolledreleasesubcutaneousformulationfortramadolhydrochloride